Hairy cell leukemia
Hairy cell leukemia
Hairy cell leukemia (HCL) is an unusual cancer of the blood. It affects B cells, a type of white blood cell (lymphocyte).
Leukemic reticuloendotheliosis; HCL; Leukemia - hairy cell
Causes, incidence, and risk factors
HCL is caused by the abnormal growth of B cells. The cells look "hairy" under the microscope because they have fine projections coming from their surface.
HCL usually leads to low numbers of normal blood cells.
The cause of this disease is unknown. It affects men more often than women. The average age of diagnosis is 55.
- Easy bruising or bleeding
- Excessive sweating (especially at night)
- Feeling full after eating only a small amount
- Recurrent infections and fevers
- Pain or fullness in the upper left belly
- Swollen lymph glands
- Weight loss
Signs and tests
Blood tests and a bone marrow biopsy can detect hairy cells. Flow cytometry is needed to make the diagnosis. Sometimes, a test called tartrate resistant acid phosphatase (TRAP) is done.
Treatment may not be needed for the early stages of this disease. Some patients may need an occasional blood transfusion.
If treatment is needed because of very low blood counts, a variety of chemotherapy drugs can be used. Drugs that may be used include cladribine, pentostatin, and rituximab.
In most cases, chemotherapy can relieve the symptoms for many years. (When the signs and symptoms go away, you are said to be in remission.) Interferon can relieve symptoms but is unlikely to lead to remission.
Removing the spleen may improve blood counts, but is unlikely to cure the disease. Antibiotics can be used to treat infections. People with low blood counts will receive growth factors and, possibly, transfusions.
Newer chemotherapy treatments have greatly improved the survival of patients with hairy cell leukemia. Most patients with hairy cell leukemia can expect to live 10 years or longer after diagnosis.
The low blood counts caused by hairy cell leukemia can lead to infections, fatigue, and excessive bleeding.
Calling your health care provider
There is no known way to prevent this disease.
Kantarjian H, O’Brien S. The chronic leukemias. In Goldman L, Schafer AI, eds. Cecil Medicine. 24th ed. Philadelphia, PA: Saunders Elsevier; 2011:chap 190.
National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Non-Hodgkin’s lymphoma. 2012. Version 2.2012.
Reviewed by:David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine. Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M. Health Solutions, Ebix, Inc.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorousstandards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information andservices. Learn more about A.D.A.M.'s editorialpolicy, editorialprocess, and privacypolicy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch.)
The information provided herein should not be used during any medical emergency or for the diagnosis or treatmentof any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions.Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 2015 A.D.A.M., Inc. Any duplication ordistribution of the information contained herein is strictly prohibited.